Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City

Patients with “penta-refractory” multiple myeloma (MM) are challenging to treat given the limited treatment options available to them. Belantamab mafodotin is the first B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate approved for the treatment of relapsed/refractory MM (RRMM). In...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaber, Waed, Abdaljalil, Ammar, Ali, Aya, Abu Haleeqa, Mohamed, Mheidly, Kayane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544041/
https://www.ncbi.nlm.nih.gov/pubmed/37791224
http://dx.doi.org/10.7759/cureus.44433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544041/
https://www.ncbi.nlm.nih.gov/pubmed/37791224
http://dx.doi.org/10.7759/cureus.44433

Ejemplares similares